News from NYU Langone Health
30,000 to take part in NYU Langone Hyrox competition
ABC7 Eyewitness News
Elizabeth Comen, MD, breast oncologist and co-director of NYU Langone Health’s Mignone Women’s Health Collaborative, is competing in HYROX, a global fitness race combining endurance running with functional strength stations like sled pushes and lunges. Highlighting NYU Langone as the first hospital to partner with the event, Dr. Comen emphasizes the philosophy that "movement is medicine," advocating for exercise as a vital component of health beyond the hospital walls. Despite personal nerves and pre-existing injuries, she prepared through intentional training with physical therapists. Dr. Comen notes that Hyrox is accessible to various fitness levels, offering individual, pair, and relay formats to encourage broad
participation.
5/30/2026
Early-life stress raises gastrointestinal disease risk
Medscape
A study in Gastroenterology led by Kara Margolis, MD, a pediatric gastroenterologist and clinical associate professor in the Department of Pediatrics at NYU Grossman School of Medicine, found that early-life stress increases the risk for long-term gastrointestinal disease. The research, involving mice and human cohorts, revealed that early adversity alters gut-nerve circuits, leading to changes in pain sensitivity and bowel function. The findings showed a significant link between maternal mental health issues and pediatric disorders of gut-brain interaction. Dr. Margolis suggests these results highlight the importance of considering a patient's life history and mood when treating GI problems.
6/01/2026
A silent kidney crisis is spreading far faster than experts expected
ScienceDaily
A global analysis co-led by researchers at NYU Langone Health found that chronic kidney disease cases rose to 788 million in 2023, making it a top 10 cause of death worldwide. The study, published in The Lancet, highlights the condition as a major public health issue. Josef Coresh, MD, PhD, director of NYU Langone's Optimal Aging Institute and the Terry and Mel Karmazin Professor of Population Health at NYU Grossman School of Medicine, emphasized the need for policymakers to prioritize the disease. Morgan Grams, MD, PhD, co-director of the Division of Precision Medicine and the Susan and Morris Mark Professor of Medicine at NYU Grossman School of Medicine, noted the disease is underdiagnosed and undertreated.
Also reporting was: WDC News 6
5/29/2026
Why renaming PCOS to PMOS matters for women’s health
The Noon
Sarah Cascante, MD, reproductive endocrinologist and infertility specialist at NYU Langone Health and clinical assistant professor NYU Grossman School of Medicine, explains the significance of renaming PCOS to Polycystic Metabolic Ovarian Syndrome (PMOS). She notes the new name accurately reflects that the condition is a whole-body metabolic disorder rather than just an ovarian issue. Characterized by insulin resistance, PMOS increases risks for heart disease and diabetes across a woman's entire lifespan. Dr. Cascante highlights that while varied symptoms like acne and weight gain often lead to delayed diagnoses, early intervention with diet, exercise, or medication can prevent long-term complications. She also clarifies that most women with PMOS can successfully build families with modern fertility treatments.
5/29/2026
Rhythms of the brain & how modern life may be disrupting w/ Dr. György Buzsáki & Dr. Robert Melillo
A MoMent of Xen
Xen Sams is joined by György Buzsáki, MD, PhD, the Biggs Professor of Neuroscience and professor of neurology at NYU Grossman School of Medicine, author of Rhythms of the Brain and The Brain From Inside Out, alongside Dr. Robert Melillo, world-renowned neuroscientist, clinician, and creator of The Melillo Method. They help us take a look inside the rhythms of the human brain and how modern life may be disrupting how our children’s early brains develop.
6/01/2026
Groundbreaking medical breakthroughs: Reversing paralysis & nerve damage once thought permanent
World Today News
European researchers have achieved a medical breakthrough by restoring some motor function in patients with complete spinal cord injuries. A study published in Nature Medicine detailed a non-invasive therapy combining electrical nerve stimulation and a neuroprotective drug cocktail, which allowed some patients to regain hand and toe movement. While the therapy is not yet FDA-approved, the article highlights that the next frontier of research is being led by institutions such as NYU Langone’s Spinal Cord Injury Center. Researchers there are focusing on advancing the treatment through combination therapies and closed-loop systems for patients with chronic injuries.
5/29/2026
The American cancer society expands colorectal cancer screening guidelines
Katie Couric Media
The American Cancer Society has updated its colorectal cancer screening guidelines, now endorsing blood and stool tests alongside colonoscopies for individuals at average risk starting at age 45. Mark Pochapin, MD, a gastroenterologist at NYU Langone Health, director of the Division of Gastroenterology & Hepatology, vice chair of Clinical Affairs, Department of Medicine, senior vice president and senior associate dean of institutional advancement and special projects, and the Sholtz-Leeds Professor of Medicine at NYU Grossman School of Medicine, notes that these newer tests are a 'two-step process,' as a positive result requires a follow-up colonoscopy. He emphasizes that colonoscopy remains the superior method because it allows for the detection and immediate removal of precancerous polyps, which is key to prevention.
Also reporting was: Yahoo Health
5/29/2026
BioLineRx (BLRX) Q1 2026 earnings transcript
The Motley Fool (U.S.)
In its Q1 2026 earnings call, BioLineRx announced the initiation of a Phase I/IIa clinical trial for GLIX1, a new molecule for treating glioblastoma. The first patient in the trial was dosed at NYU Langone Health under the supervision of Alexandra Miller, MD, chief of Neuro-oncology, co-director of the Brain and Spine Tumor Center at NYU Langone's Perlmutter Cancer Center, and associate professor in the Departments of Neurology, Medicine and Neurosurgery at NYU Grossman School of Medicine. The trial, which also includes Northwestern University and Moffit Cancer Center, aims to establish a recommended dose and assess safety and preliminary efficacy for the aggressive brain cancer.
Also reporting was: Yahoo Finance, American Banking and Market News
5/29/2026
AI is taking over therapy notes but patients say they never signed up for a third listener
The Mary Sue
Therapists are increasingly using AI tools to record sessions and automate clinical notes, raising significant patient privacy and trust issues. The article highlights patient concerns about their private conversations being processed by algorithms without explicit consent. Kellie Owens, PhD, an assistant professor of medical ethics at NYU Grossman School of Medicine, notes that HIPAA compliance does not prevent major data breaches. Owens also argues that written consent forms are often insufficient for ensuring patients make an informed choice, and verbal consent should be required for any recordings.
5/29/2026
SCIENMAG
At the 2026 American Society of Clinical Oncology Annual Meeting, researchers from NYU Langone Health's Perlmutter Cancer Center presented several new findings. A trial led by Janice Mehnert, MD, director of Melanoma Medical Oncology Program and associate director of Clinical Research, explored pembrolizumab for Merkel cell carcinoma. A study by Daniel J. Becker, MD, medical oncologist, revealed socioeconomic disparities in lung cancer screening. Other advances include a machine-learning model for prostate cancer by David R. Wise, MD, oncologist, service chief, Genitourinary Medical Oncology Program, Perlmutter Cancer Center, research on immunotherapy timing for breast cancer by Iris Zhi, MD, interim chief of Division of Hematology and Oncology and medical director of Clinical Operations, Medical Oncology, Perlmutter Cancer Center -- Long Island, and a novel CAR T-cell therapy trial for solid tumors led by Salman R. Punekar, MD, a medical oncologist at NYU Langone’s Perlmutter Cancer Center.
5/29/2026
Steve Popper: 'If no one gets injured' . . . that's the big key
Newsday
Following an injury to New York Knicks player Mitchell Robinson, who sustained a broken right pinkie, an expert from NYU Langone Health provided commentary. Daniel Kaplan, MD, a sports orthopedic surgeon at the Joseph S. and Diane H. Steinberg Ambulatory Care Center—Cobble Hill, explained that since Robinson is not a shooting player, his primary contributions of rebounding and defense are less affected. Dr Kaplan stated that while a return for the NBA Finals is conceivable with bracing or taping, Robinson would remain at risk for reinjuring the finger if it is not fully healed before he returns to play.
Also reporting was: FOX 5
6/01/2026
Can intensive lifestyle changes reverse early Alzheimer’s symptoms?
Everyday Health
A combination of daily behaviors, rather than a single habit, offers the most significant benefit for brain health. Yu Chen, PhD, MPH, professor of epidemiology at NYU Grossman School of Medicine, states that key practices include physical activity, proper nutrition, stress management, prioritizing sleep, social connections, and mental stimulation. The article details how to incorporate these habits, such as aiming for regular aerobic exercise, following a Mediterranean-style diet, maintaining a consistent sleep schedule, and engaging in cognitive training to support brain function and potentially reverse early Alzheimer’s symptoms.
5/29/2026
Oceanside Library Special Needs Resource Fair draws more than 600 attendees
LIHerald.com
The Oceanside Library's second annual Special Needs Resource Fair on May 3 attracted more than 600 attendees, connecting families with local support services and educational resources. The event was sponsored by NYU Langone Health and featured over 20 organizations. Presentations focused on topics such as supported decision-making, special needs estate planning, and care gaps in autism across the lifespan. The fair highlights the library's commitment to accessibility and inclusion, aiming to help families build connections with support networks. Organizers plan to expand the event in the future.
5/29/2026
NJ.com
A New Jersey man, Marty Novar, developed encephalitis from the rare tick-borne Powassan virus in November 2025, leading to severe memory loss. He was treated at NYU Langone, where doctors struggled to identify the cause of his brain inflammation. Catherine Valentine, MD, clinical assistant professor in the Division of Infectious Diseases at NYU Grossman School of Medicine, suspected a tick-borne illness and, after specialized testing, confirmed the Powassan virus diagnosis. The article details Novar's difficult recovery and highlights the increasing prevalence of the virus, which has no specific treatment or vaccine.
Also reporting was: Yahoo
5/30/2026
Toxic plastics causing ‘silent epidemic of kids with lower IQs,’ pediatrician tells RFK Jr.
The Defender
Leonardo Trasande, MD, MPP, director of the Division of Environmental Pediatrics, vice chair of pediatric research, the Jim G. Hendrick, MD Professor of Pediatrics and a professor of population health at NYU Grossman School of Medicine, warned that plastics pose an urgent threat to human health, particularly for children. He described a 'silent epidemic of kids with lower IQs' due to exposure to chemicals in plastics, which can cause developmental, hormonal, and neurological harm. Trasande noted that children are uniquely susceptible because they consume more food and water pound for pound. The discussion coincided with the launch of a $144 million federal initiative to study and remove microplastics from the human body.
5/29/2026
6 ways to raise a resilient kid without being too tough
Parents
In an article about raising resilient children, Joseph Laino, PsyD, psychologist and assistant director at Sunset Terrace Family Health Center at NYU Langone, explains that building resilience involves teaching children to be prepared for life's challenges. He advises that secure attachments foster self-confidence and emotional regulation. Dr. Laino suggests parents should allow children to struggle slightly while providing a 'scaffolding of support' so they do not feel alone. He also recommends validating a child's feelings of disappointment before problem-solving and modeling healthy coping mechanisms. Maintaining routines for sleep, nutrition, and exercise can also provide a strong foundation for managing daily stressors.
Also reporting was: Aol, Yahoo Life
5/30/2026
TIME
The family of former YouTube CEO Susan Wojcicki, who died from lung cancer despite being a non-smoker, has launched a foundation to fund research and advocate for broader screening guidelines. The article notes that up to 20% of new lung cancer diagnoses are in non-smokers. It highlights a study by Elaine Shum, MD, an oncologist, director of Cancer Screening Program at NYU Langone’s Perlmutter Cancer Center, and assistant professor of medicine at NYU Grossman School of Medicine. The study found a higher cancer rate in at-risk Asian American women than in a national trial of smokers. Wojcicki received her final treatment at Memorial Sloan Kettering.
5/29/2026
Antibiotic effects on the gut detected up to 8 years later
Medscape
New research in Nature Medicine shows certain antibiotics can alter the gut microbiome for up to eight years, with clindamycin and fluoroquinolones having the strongest effects on species diversity. The study found that even a single course could have long-lasting impacts. Commenting on the findings, Adam Faye, MD, director of clinical research at NYU Langone Health’s Inflammatory Bowel Disease Center and assistant professor of medicine and population health at NYU Grossman School of Medicine, said the data supports previous suspicions about the long-term influence of antibiotics. He emphasized that understanding these effects on clinical outcomes will be critical for putting the research into proper context and guiding antibiotic use.
6/01/2026
‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long
The Washington Post
A landmark clinical trial for the pancreatic cancer drug daraxonrasib has demonstrated the ability to double patient survival times compared to standard chemotherapy. By targeting the common KRAS mutation, the pill extended median survival to 13.2 months and kept tumors in check twice as long as traditional treatments. Anirban Maitra, MD, director of NYU Langone's Laura and Isaac Perlmutter Cancer Center and associate dean for cancer research, as well as a member of the faculty of NYU Grossman School of Medicine, described the results as a "wonderful foundation" for developing even more potent combination therapies. While acknowledging that the cancer eventually builds resistance, Maitra emphasized that science is moving at "breakneck speed" to create longer-lasting treatments for this historically lethal disease.
Also reporting was: Science News, Reader Supported News
5/31/2026
When to retreat, when to switch in CLL treatment decision-making: Adam Kittai, MD
American Journal of Managed Care
In an interview, Adam Kittai, MD, director of the CLL Program at Perlmutter Cancer Center, director of the Lymphoma Program at Perlmutter Cancer Center - Long Island, and member of the faculty at NYU Grossman Long Island School of Medicine, discussed treatment decision-making for chronic lymphocytic leukemia (CLL). He addressed the challenges when initial treatments, such as BTK inhibitors and venetoclax-based regimens, stop working. Kittai noted the lack of definitive data on how patients fare after moving sequentially through these treatments but expressed confidence in their second-line performance. He also explored questions around retreatment with the same regimen and the use of triplet therapies for specific patient groups.
5/31/2026
How the Tempus AI (TEM) investment story is shifting as analysts rework their models
Yahoo Finance
The investment outlook for Tempus AI is mixed as analysts adjust financial models, though its fair value target remains steady at $67.20 per share. Bullish analysts point to long-term potential, with H.C. Wainwright citing ongoing partnerships with organizations including NYU Langone Health as key to building the company's data platforms and molecular profiling offerings. However, other firms have trimmed their targets due to execution risk. Tempus AI also recently received FDA approval for a tumor-only indication for its Tempus xT CDx comprehensive genomic profiling assay for solid tumors.
Also reporting was: Yahoo Finance UK
5/30/2026
Cosmetic interventions are booming. Many say ethical conversations are lagging
YourSun.com
As cosmetic interventions like Botox and Ozempic become more common, a growing number of theologians and bioethicists are calling for more conversation around the ethical implications. According to Arthur L. Caplan, PhD, the Drs. William F. and Virginia Connolly Mitty Professor of Bioethics and founding head of the Division of Medical Ethics at NYU Grossman School of Medicine’s Department of Population Health, bioethics training does not prioritize plastic surgery, meaning surgeons often must set their own boundaries. The article notes that while many religions condemn vanity, there is little official guidance on these procedures, leading to a wide spectrum of personal stances.
5/31/2026
Telehealth booms as demand for GLP-1s surges and questions mount about safety, oversight
KFF Health News
The increasing demand for GLP-1 weight loss drugs has fueled a telehealth boom, raising concerns about patient safety and oversight. The article highlights cases where patients were hospitalized after receiving dangerously high doses from online companies. According to Arthur L. Caplan, PhD, the Drs. William F. and Virginia Connolly Mitty Professor of Bioethics and founding head of the Division of Medical Ethics at NYU Grossman School of Medicine’s Department of Population Health, some telehealth providers fail to ensure patients understand the risks associated with injectable drugs, calling the consent process inadequate. The report also notes a surge in medication errors reported to the FDA and legal challenges against telehealth companies by drug manufacturers.
6/01/2026
